HIGHER-RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGHER-RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGHER-RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental antibody offers hope for Tough-to-Treat leukemia patients
Disease control Recruiting nowThis is the first human trial of an experimental antibody called GEN3018 for adults with advanced blood cancers that have returned or resisted previous treatments. The main goals are to find a safe dose and see if the drug shows early signs of fighting the cancer. Up to 78 partic…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug trial targets tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called CCS1477 (inobrodib) in people with advanced blood cancers that have returned or stopped responding to standard treatments. The study will give the drug alone and in combination to about 250 patients to check if it is s…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Global race for better MDS treatment: can new drug combo extend lives?
Disease control Recruiting nowThis large, late-stage trial is testing if adding a new drug called lisaftoclax to the standard treatment (azacitidine) helps people with newly diagnosed high-risk MDS live longer. About 490 participants worldwide will be randomly assigned to receive either the new combination or…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC